Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $511.09, for a total value of $4,855,355.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $165,819,572.87. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $492.02 on Thursday. The firm has a market capitalization of $21.10 billion, a PE ratio of 17.60, a PEG ratio of 2.56 and a beta of 0.56. The stock’s fifty day moving average is $528.12 and its 200 day moving average is $539.79. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in shares of United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after buying an additional 33,229,108 shares during the period. BlackRock Inc. purchased a new position in shares of United Therapeutics during the second quarter valued at $2,868,735,000. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC purchased a new stake in United Therapeutics in the second quarter worth about $450,140,000. Finally, Norges Bank bought a new position in United Therapeutics during the 4th quarter worth about $293,418,000. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.